Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

362

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

June 30, 2014

Study Completion Date

September 24, 2020

Conditions
Prostate Adenocarcinoma
Interventions
DRUG

Short term androgen deprivation

"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months"

DRUG

Long term androgen deprivation

"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"

RADIATION

Short term androgen deprivation

Minimum dose of 76 Gy (range 76-82 Gy)

RADIATION

Long term androgen deprivation

Minimum dose of 76 Gy (range 76-82 Gy)

Trial Locations (1)

28006

Hospital Universitario de la Princesa, Madrid

All Listed Sponsors
lead

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

OTHER

NCT02175212 - Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer | Biotech Hunter | Biotech Hunter